BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025Accesswire • 11/03/25
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipelineProactive Investors • 10/31/25
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/28/25
AstraZeneca found in breach of industry code over Symbicort marketing, industry body saysReuters • 10/24/25
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff ReprieveZacks Investment Research • 10/13/25
AstraZeneca's drug pricing deal with Trump far from clear result, say analystsProactive Investors • 10/13/25
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMOBusiness Wire • 10/13/25